Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

USB Piper Ups Ilex Oncology to 'Outperform'


USB Piper upgraded Ilex Oncology (ILXO) to outperform from market perform.

Analyst Mark Shoenenbaum says his upgrade reflects increased confidence in growth prospects for Ilex's Campath treatment for chronic lymphocytic leukemia. He raised the second-quarter Campath sales estimate to $15.2 million, from $14 million, and upped the $59 million 2003 estimate to $61 million and sees $106 million for 2004.

Shoenenbaum says momentum for Campath is likely sustainable over the long term. He says beyond Campath, pipeline products should provide consistent news flow. Shoenenbaum believes the two most promising products are Clofarabine and ILX-651. He raised his $17 target to $23. He sees a $1.33 2003 loss, and a 50-cent 2004 loss.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus